Suppr超能文献

精神分裂症患者对长效注射治疗的态度及其影响因素:基于社区的横断面调查。

Attitude and influencing factors of patients with schizophrenia toward long-acting injections: A community-based cross-sectional investigation in China.

机构信息

Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.

Mental Health Subcentre of Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.

出版信息

Front Public Health. 2022 Oct 10;10:951544. doi: 10.3389/fpubh.2022.951544. eCollection 2022.

Abstract

BACKGROUND

Low prescription rates of antipsychotic long-acting injections (LAIs) may be a major challenge in the prevention and treatment of schizophrenia. However, there are few studies on the usage and attitude toward LAIs among community-based patients with schizophrenia.

METHODS

A large community-based cross-sectional investigation was conducted among 6,336 patients with schizophrenia from Shanghai, China from March 1 to June 30, 2021. The structured Attitude and Status toward Treatment of Community Patients with Schizophrenia Questionnaire (AST-CSQ) was used to investigate the attitude and influencing factors of community-dwelling patients with schizophrenia toward LAIs.

RESULTS

Among the 6,336 participants, the average age was 49.28 ± 11.23. The rate of agreement to LAI antipsychotics among participants was 3.16% ( = 200). The family financial resources, care ability, and disease course of the LAIs group were less than those of the non-LAIs group. However, the LAIs group had higher immediate family guardianship, social activity, previous hospitalization, number of hospitalization, outpatient adherence, previous antipsychotic use, antipsychotic adherence, and attitude toward oral antipsychotics than the non-LAIs group, with significant differences between the two groups ( < 0.05). Furthermore, age (β = -0.036, OR 0.964, 95% CI 0.947-0.982), marital status (β = 0.237, OR 1.267, 95% CI 1.002-1.602), care ability (β = 0.709, OR 2.032, 95% CI 1.437-2.875), outpatient adherence (β = -0.674, OR 0.510, 95% CI 0.358-0.725), antipsychotic adherence (β = 0.920, OR 2.509, 95% CI 1.092-5.764), and attitude toward oral antipsychotics (β = -1.357, OR 0.258, 95% CI 0.103-0.646) were significant predictors of attitude toward LAI antipsychotics ( < 0.05).

CONCLUSIONS

The community-dwelling patients with schizophrenia in China had a low willingness to use LAIs. Patients of a younger age, more hospitalizations, and a shorter course of disease were prone to be more willing to accept LAIs. The patients' age, marital status, care ability, outpatient adherence, antipsychotic adherence, and attitude toward oral antipsychotics were important predictor of patients' attitudes toward LAIs. Under the global deinstitutionalized management model of mental disorders, these results highlight an urgent problems for public mental health service providers and policy-makers and provide more solutions for them.

摘要

背景

抗精神病药长效注射剂(LAIs)的处方率低可能是预防和治疗精神分裂症的主要挑战。然而,针对社区精神分裂症患者使用和对 LAI 的态度的研究较少。

方法

2021 年 3 月 1 日至 6 月 30 日,对来自中国上海的 6336 名社区精神分裂症患者进行了一项大型社区横断面调查。采用社区精神分裂症患者治疗态度与现状问卷(AST-CSQ)调查社区精神分裂症患者对 LAI 的态度及其影响因素。

结果

在 6336 名参与者中,平均年龄为 49.28 ± 11.23 岁。参与者对 LAI 抗精神病药的同意率为 3.16%(=200)。LAIs 组的家庭经济资源、照顾能力和疾病病程均低于非 LAI 组。然而,LAIs 组的直系家属监护、社会活动、既往住院、住院次数、门诊依从性、既往抗精神病药使用、抗精神病药依从性和对口服抗精神病药的态度均高于非 LAI 组,两组差异有统计学意义(<0.05)。此外,年龄(β=-0.036,OR 0.964,95%CI 0.947-0.982)、婚姻状况(β=0.237,OR 1.267,95%CI 1.002-1.602)、照顾能力(β=0.709,OR 2.032,95%CI 1.437-2.875)、门诊依从性(β=-0.674,OR 0.510,95%CI 0.358-0.725)、抗精神病药依从性(β=0.920,OR 2.509,95%CI 1.092-5.764)和对口服抗精神病药的态度(β=-1.357,OR 0.258,95%CI 0.103-0.646)是影响患者对 LAI 抗精神病药态度的显著预测因素(<0.05)。

结论

中国社区精神分裂症患者使用 LAI 的意愿较低。年龄较小、住院次数较多、病程较短的患者更愿意接受 LAI。患者的年龄、婚姻状况、照顾能力、门诊依从性、抗精神病药依从性和对口服抗精神病药的态度是影响患者对 LAI 态度的重要预测因素。在全球精神障碍去机构化管理模式下,这些结果凸显了精神卫生服务提供者和政策制定者面临的紧迫问题,并为他们提供了更多的解决方案。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验